Inventor
CHAO JIANHUA
US28 patents
⚠️ This page may combine multiple inventors who share the name “CHAO JIANHUA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
10 patentsUS6878709B2Apr 12, 2005
3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
SCHERING CORP20 citations92
US7964646B2Jun 21, 2011
3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
SCHERING CORP10 citations82
US7947720B2May 24, 2011
3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
SCHERING CORP10 citations82
US7635705B2Dec 22, 2009
Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
SCHERING CORP2 citations62
US7338968B2Mar 4, 2008
Thiadiazoles AS CXC- and CC- chemokine receptor ligands
SCHERING CORP4 citations62
US7326729B2Feb 5, 2008
CXCR1 and CXCR2 chemokine antagonists
SCHERING CORP6 citations62
US7691856B2Apr 6, 2010
Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
SCHERING CORP3 citations61
US7671212B2Mar 2, 2010
Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
SCHERING CORP4 citations61
US7960433B2Jun 14, 2011
Treatment of chemokine mediated diseases
SCHERING CORP4 citations58
US7786149B2Aug 31, 2010
Thiadiazoles as CXC- and CC- chemokine receptor ligands
SCHERING CORP0 citations51
ARDELYX INC
5 patentsUS11091482B2Aug 17, 2021
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
ARDELYX INC3 citations70
US10793568B2Oct 6, 2020
Hormone receptor modulators for treating metabolic conditions and disorders
ARDELYX INC4 citations70
US12209088B2Jan 28, 2025
Hormone receptor modulators for treating metabolic conditions and disorders
ARDELYX INC0 citations60
US11718619B2Aug 8, 2023
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
ARDELYX INC0 citations60
US11753410B2Sep 12, 2023
Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders
ARDELYX INC0 citations52
THERAVANCE BIOPHARMA R&D IP LLC
3 patentsUS11155549B2Oct 26, 2021
Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
THERAVANCE BIOPHARMA R&D IP LLC5 citations81
US11845747B2Dec 19, 2023
Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
THERAVANCE BIOPHARMA R&D IP LLC0 citations60
US11439641B2Sep 13, 2022
Pyrimidine JAK inhibitors for the treatment of skin diseases
THERAVANCE BIOPHARMA R&D IP LLC0 citations48
MERCK SHARP & DOHME
3 patentsUS8383818B2Feb 26, 2013
Functionally selective alpha2C adrenoreceptor agonists
MERCK SHARP & DOHME5 citations72
US8569312B2Oct 29, 2013
Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators
MERCK SHARP & DOHME0 citations51
US8476274B2Jul 2, 2013
Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators
MERCK SHARP & DOHME0 citations51